Interim Management Statement
May 12, 2020 11:54 ET
|
Hargreave Hale AIM VCT plc
Interim Management Statement Introduction This interim management statement covers the first half of the 2019/20 financial year, 1 October 2019 to 31 March 2020. Investment performance measures...
Annual Financial Report
February 13, 2020 12:03 ET
|
Octopus AIM VCT 2 plc
Octopus AIM VCT 2 plc Final Results 13 February 2020 Octopus AIM VCT 2 plc, managed by Octopus Investments Limited, today announces the final results for the year ended 30...
Final Results
December 19, 2019 11:59 ET
|
Hargreave Hale AIM VCT plc
Preliminary Announcement of Final Results for the year ended 30 September 2019 Strategic report The report has been prepared by the Directors in accordance with the...
Half-year report
October 22, 2019 12:13 ET
|
Octopus AIM VCT PLC
Half-yearly Results 22 October 2019 Octopus AIM VCT plc, managed by Octopus Investments Limited, today announces the half-yearly results for the six months ended 31 August 2019. These results were...
Half-year report
July 24, 2019 07:15 ET
|
Octopus AIM VCT 2 plc
Half-yearly Results 24 July 2019 Octopus AIM VCT 2 plc, managed by Octopus Investments Limited, today announces the half-yearly results for the six months ended 31 May 2019. These results were...
Half-year report
June 27, 2019 11:08 ET
|
Hargreave Hale AIM VCT plc
Hargreave Hale AIM VCT PlcUnaudited Interim Results for the six month period ending 31 March 2019 FINANCIAL HIGHLIGHTS Ordinary Shares (as at 31 March):31 March 201931 March...
Annual Diaceutics Report Illuminates State of Diagnostic Ecosystem in the Pharmaceutical Industry
December 14, 2016 07:34 ET
|
Diaceutics
DUNDALK, IRELAND and PARSIPPANY, NJ--(Marketwired - Dec 14, 2016) - Today, Diaceutics, a global group of experts from the laboratory, diagnostics and pharmaceutical industries, enabling...
Data From Labceutics' Infectious Disease Lab Mapping Program Accepted as a Late-Breaker at ICTMM 2016
September 14, 2016 08:06 ET
|
Labceutics
PARSIPPANY, NJ--(Marketwired - Sep 14, 2016) - Labceutics (part of the Diaceutics Group) announced today that data from one of its infectious disease lab mapping initiatives has been accepted as a...
Cancer Genetics, Inc. Expands Its Immuno-Oncology Franchise With The Addition of The FDA-Approved VENTANA PD-L1 (SP142) Assay As A Complementary Diagnostic Test For TECENTRIQ™
June 29, 2016 07:58 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 29, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and...
Bioceutics Wins First Place Award at DxMA Global Marketing Summit
June 09, 2016 08:02 ET
|
Bioceutics
PARSIPPANY, NJ--(Marketwired - Jun 9, 2016) - Bioceutics, a specialized marketing, education and communications division of Diaceutics, the leading provider of personalized medicine integration...